The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation-Reference-Cited by-同舟云学术

The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation

Published:1975-11 Issue:1 Volume:34 Page:181-187
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Braestrup Claus,Andersen Henning,Randrup Axel

Publisher

Elsevier BV

Subject

Pharmacology

Reference32 articles.

1. Separation, detection and quantitative analysis of urinary β-phenylethylamine;Boulton;J. Chromatogr.,1971

2. Identification of free and conjugated 3-methoxy-4-hydroxyphenylglycol (MOPEG) in rat brain by gas chromatography and mass fragmentography;Braestrup;Anal. Biochem.,1973

3. Accumulation and disappearance of noradrenaline and its major metabolites synthesized from intraventricularly injected 3H-dopamine in the rat brain;Braestrup;J. Neurochem.,1974

4. A comparison of the pharmacological and biochemical properties of substrate-selective monoamine oxidase inhibitors;Christmas;Brit. J. Pharmacol.,1972

5. The use of amphetamine induced stereotyped behaviour as a model for the experimental evaluation of antiparkinson agents;Costall;Arzneim. Forsch. (Drug Res.),1972

Cited by 131 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Traumatic Brain Injury: Role in Induction and Progression of Neurodegenerative Disorders;Research Journal of Pharmacy and Technology;2024-04-22

2. Striking Neurochemical and Behavioral Differences in the Mode of Action of Selegiline and Rasagiline;International Journal of Molecular Sciences;2023-08-28

3. Revisiting the Role of Astrocytic MAOB in Parkinson’s Disease;International Journal of Molecular Sciences;2022-04-18

4. Pharmacological and non-pharmacological interventions of depression after traumatic brain injury: A systematic review;European Journal of Pharmacology;2019-12

5. Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer’s Disease;Journal of Pharmacology and Experimental Therapeutics;2017-06-22